Trial results presented at US oncology conference suggest ribociclib could be gamechanging and boost survival rate significantly
Thousands of women with the world’s most common form of breast cancer could benefit from a blockbuster drug that helps them live longer and cuts the risk of the disease returning by a quarter.
More than 2 million people globally are diagnosed each year with the disease, which is the world’s most prevalent cancer. Although treatments have improved in recent decades, many patients will later experience the cancer returning. If a recurrence does occur, it is often at a more advanced stage.
About Author
More Stories
Sperm from cancer-risk donor used to conceive at least 67 children across Europe
Fortnite unavailable on iPhones globally after Apple rejects App Store release
Elon Musk shows he still has the White House’s ear on Trump’s Middle East trip